Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis sales

This article was originally published in The Tan Sheet

Executive Summary

Double-digit OTC growth drove Novartis Consumer Health first-quarter sales up 4% to $1.82 bil., the firm reports in an April 24 earnings call. "Strong expansion" in OTCs due to the acquisition of Bristol-Myers Squibb's consumer business was one major factor; the purchase, completed in August 2005, brought in brands such as Excedrin and Bufferin pain relievers (1"The Tan Sheet" Sept. 5, 2005, In Brief). Novartis cited a "good" U.S. cough/cold season as a driver of first-quarter revenue; brands include Theraflu, Comtrex and Triaminic. Higher sales of the analgesic Voltaren (diclofenac) in Europe also contributed. Consumer Health operating income increased 60% to $458 mil., mainly due to a $129 mil. gain from the divestment of the Nutrition & Sante functional food business, completed in February 2006 (2"The Tan Sheet" Dec. 5, 2005 In Brief). Overall net sales were up 13% to $8.3 bil., while net income grew 32% to $1.96 bil....

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts